Ardelyx (ARDX) Total Liabilities (2013 - 2026)
Ardelyx (ARDX) reported Total Liabilities of $355.9 million for Q1 2026, up 34.54% on a YoY basis from $264.5 million in Q1 2025, and up 6.34% quarter-over-quarter from $334.7 million in Q4 2025.
Ardelyx (ARDX) Total Liabilities (2013 - 2026) Analysis & Trends
Ardelyx has reported Total Liabilities for 14 years, with the latest figure at $355.9 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities rose 34.54% year-over-year to $355.9 million; the trailing twelve-month figure through Mar 2026 stood at $355.9 million (up 34.54% YoY), and the FY2025 full-year result was $334.7 million, up 27.5% from the prior year.
- Total Liabilities for Q1 2026 stood at $355.9 million, up from $334.7 million in the prior quarter.
- The five-year high for Total Liabilities was $355.9 million in Q1 2026, with the low at $65.2 million in Q1 2022.
- Historically, Total Liabilities has averaged $188.0 million across 5 years, with a median of $191.5 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities retreated 17.95% — and 2024, when it soared 123.19%.
- Ardelyx's Total Liabilities stood at $91.7 million in 2022, then soared by 42.54% to $130.8 million in 2023, then soared by 100.72% to $262.5 million in 2024, then gained by 27.5% to $334.7 million in 2025, then increased by 6.34% to $355.9 million in 2026.
- The last three Total Liabilities figures came in at $355.9 million (Q1 2026), $334.7 million (Q4 2025), and $331.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.74 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.48 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 731.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 10.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 19.51 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 943,068.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.12 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 137.56 Mn |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | 355.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 355.89 Mn |
| Dec 31, 2025 | 334.66 Mn |
| Sep 30, 2025 | 331.89 Mn |
| Jun 30, 2025 | 327.24 Mn |
| Mar 31, 2025 | 264.52 Mn |
| Dec 31, 2024 | 262.47 Mn |
| Sep 30, 2024 | 209.57 Mn |
| Jun 30, 2024 | 196.50 Mn |
| Mar 31, 2024 | 191.49 Mn |
| Dec 31, 2023 | 130.76 Mn |
| Sep 30, 2023 | 98.22 Mn |
| Jun 30, 2023 | 88.04 Mn |
| Mar 31, 2023 | 91.60 Mn |
| Dec 31, 2022 | 91.74 Mn |
| Sep 30, 2022 | 77.81 Mn |
| Jun 30, 2022 | 78.57 Mn |
| Mar 31, 2022 | 65.22 Mn |
| Dec 31, 2021 | 67.30 Mn |
| Sep 30, 2021 | 89.42 Mn |
| Jun 30, 2021 | 87.41 Mn |